Mod GRF (1-29), Ipamorelin Blend is a lyophilized research material containing two synthetic peptides: Modified GRF (1-29) and Ipamorelin. The blend is intended exclusively for controlled laboratory research involving growth hormone-releasing hormone receptor pathways, growth hormone secretagogue receptor pathways, peptide characterization, and GH-axis research models.
Modified GRF (1-29) is a synthetic analog associated with growth hormone-releasing hormone receptor research. Ipamorelin is a synthetic pentapeptide commonly examined in assays involving the growth hormone secretagogue receptor, also identified as GHS-R1a. Combining these materials permits comparative analysis of two distinct receptor-associated pathways within a single controlled research framework.
Nordsci provides lot-specific analytical documentation for research materials. Researchers should review the applicable Certificate of Analysis before beginning laboratory work.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), Ipamorelin Blend is a lyophilized research material containing two synthetic peptides: Modified GRF (1-29) and Ipamorelin. The blend is intended exclusively for controlled laboratory research involving growth hormone-releasing hormone receptor pathways, growth hormone secretagogue receptor pathways, peptide characterization, and GH-axis research models.
Modified GRF (1-29) is a synthetic analog associated with growth hormone-releasing hormone receptor research. Ipamorelin is a synthetic pentapeptide commonly examined in assays involving the growth hormone secretagogue receptor, also identified as GHS-R1a. Combining these materials permits comparative analysis of two receptor-associated pathways within a single controlled research framework.
Lot-specific analytical documentation is available for review before the material is incorporated into an authorized laboratory procedure.
FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR CLINICAL, DIAGNOSTIC, THERAPEUTIC, VETERINARY, FOOD, COSMETIC, OR DIETARY-SUPPLEMENT USE.
Modified GRF (1-29), Ipamorelin Blend – Research Specifications:
| Product Identity | Modified GRF (1-29), Ipamorelin Blend |
| Components | Modified GRF (1-29) and Ipamorelin |
| Material Type | Synthetic peptide blend |
| Form | Lyophilized powder |
| Molecular Formula | Component-specific; consult the applicable analytical documentation |
| Molecular Weight | Component-specific; consult the applicable analytical documentation |
| Sequence | Component-specific; consult the applicable analytical documentation |
| CAS Information | Component-specific, where applicable |
| Purity and Identity | Refer to the lot-specific Certificate of Analysis for reported analytical results |
| Analytical Testing | Lot-specific testing methods and results are identified in the applicable COA |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture according to laboratory SOPs |
| Research Use Only | Not for human consumption, animal consumption, veterinary use, diagnostic use, or clinical application |
Modified GRF (1-29) is a synthetic peptide analog associated with laboratory investigation of growth hormone-releasing hormone receptor systems. Its defined peptide structure makes it relevant to receptor-binding studies, analytical-method development, peptide comparison, and controlled research involving GHRH-associated pathways.
Ipamorelin is a synthetic pentapeptide examined in laboratory systems involving the growth hormone secretagogue receptor. It may be evaluated through receptor-binding assays, analytical characterization, stability testing, and other validated in vitro methods.
The combined material provides a standardized research format for examining two receptor-associated peptide components under the same experimental conditions. Researchers may compare the blend with component-specific controls to differentiate individual and combined assay observations.
Researchers examining the individual materials can review CJC-1295 without DAC, commonly associated with Modified GRF (1-29) research, and Ipamorelin.
Important Research Notice: Lot-specific Certificates of Analysis are available for analytical review, internal documentation, and batch traceability.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. IT IS NOT A DRUG, FOOD, COSMETIC, OR DIETARY SUPPLEMENT. IT IS NOT FOR HUMAN OR ANIMAL CONSUMPTION AND IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
The blend may be examined in validated laboratory models addressing the analytical and receptor-level characteristics associated with GH-axis signaling architecture. Research should remain limited to controlled laboratory systems and appropriately documented methods.
Modified GRF (1-29) and Ipamorelin are associated with different receptor pathways examined in GH-axis research. In vitro assay designs may use the blend to compare pathway-specific interactions, receptor-binding characteristics, and method-dependent assay observations.
Qualified laboratories may use validated cell-free, receptor-binding, or in vitro assay systems to examine analytical markers relevant to peptide-receptor research. Findings should be interpreted only within the limitations of the selected laboratory model.
Researchers may compare the blend with individual component controls, reference standards, or other peptide preparations. Comparative studies may examine analytical identity, chromatographic behavior, stability, receptor-binding characteristics, and method-specific assay observations.
The Modified GRF (1-29), Ipamorelin Blend should be handled only by qualified personnel in an appropriately equipped laboratory. Standard procedures should address contamination control, sample identification, environmental conditions, chain of custody, storage monitoring, and experimental documentation.
Protocol Design Considerations: Assay type, control selection, sample preparation, analytical instrumentation, environmental conditions, and collection timing should be standardized before testing. Researchers are responsible for determining whether the material is appropriate for a particular laboratory method.
No information on this page should be interpreted as dosing, administration, preparation, clinical, veterinary, or consumer-use guidance.
The applicable Certificate of Analysis contains lot-specific information concerning product identity, purity, analytical methods, and reported test results. Researchers should match the lot number shown on the product container with the corresponding COA before incorporating the material into a laboratory protocol.
Analytical documentation may be retained with procurement records, inventory logs, method records, and other internal quality-control documentation.
Nordsci Peptides supplies Modified GRF (1-29), Ipamorelin Blend exclusively as a laboratory research material. Product selection should be based on lot traceability, analytical documentation, storage requirements, institutional policies, and compatibility with the intended research method.
IMPORTANT: This material is not FDA-approved for human or veterinary use. It is not intended for human or animal consumption or for use as a drug, food, cosmetic, dietary supplement, diagnostic material, or therapeutic product. The purchaser is responsible for compliance with all applicable laws, regulations, institutional requirements, and laboratory safety procedures.
